Pan-cancer analysis showed that RBM39 is aberrantly expressed in multiple cancers and is significantly associated with patient prognosis, suggesting its diagnostic value, and RBM39 may serve as a potential diagnostic and therapeutic target for HNSC.
Abstract
RBM39 plays an important regulatory role in multiple cancers. However, its systematic function across pan-cancer and its specific mechanism in head and neck squamous cell carcinoma (HNSC) remain unclear.
In this study, we performed pan-cancer expression and survival analyses based on TCGA and GTEx databases, combined with copy number variation and DNA methylation analyses to explore the regulatory mechanisms of RBM39. GSEA and functional enrichment were used to identify associated signaling pathways. In HNSC cells, qRT-PCR, CCK-8, Transwell, and tumor sphere formation assays were performed to validate its biological functions. In addition, RM2Target and SRAMP databases were used to investigate m
6
A-mediated regulation of RBM39, and RNA stability assays were performed for validation. The relationship between RBM39 and tumor immune infiltration as well as drug sensitivity was also evaluated.
Pan-cancer analysis showed that RBM39 is aberrantly expressed in multiple cancers and is significantly associated with patient prognosis, suggesting its diagnostic value. In HNSC, RBM39 is significantly upregulated and positively correlated with tumor stage. In vitro experiments demonstrated that RBM39 knockdown significantly inhibited tumor cell proliferation and migration. Mechanistically, RBM39 activates the Wnt signaling pathway and upregulates key target genes, including CTNNB1, SOX2, OCT4, and MYC, thereby promoting cancer stem cell self-renewal. Furthermore, METTL3-mediated m
6
A modification enhances RBM39 mRNA stability and increases its expression.
RBM39 acts as a key oncogenic factor in HNSC by promoting tumor progression and stemness through an m
6
A-dependent mechanism and Wnt pathway activation. It also contributes to an immunosuppressive microenvironment and drug resistance. RBM39 may serve as a potential diagnostic and therapeutic target for HNSC.
Tetratricopeptide repeat domain protein 39B (TTC39B) is a lipid metabolism–related gene recently implicated in cholesterol regulation. However, its clinical and biological relevance in human cancers remains undefined.
Based on multi-omics data from the Cancer Genome Atlas (TCGA) pan-cancer dataset represen...
Hui-Juan Yi, Yan Wang, Chen-Hao Zhao et al.· BMC Medical Genomics· 0 citations
HIST1H4L was significantly upregulated in SCLC tumors versus normal tissues and enriched in DNA transcription-related pathways and correlated with poor patient survival; critically, high HIST1H4L expression correlated with poor patient survival.
Shi-Cheng Feng, Min Feng, Zhi-Qiang Lu et al.· Frontiers in Oncology· 0 citations
Functional and rescue experiments support MAPK/ERK signaling as a partial mediator of PAXX-associated malignant phenotypes and EMT-related alterations in CRC progression and its association with the tumor immune microenvironment.
Jin-Zhong Cao, Zi-Jing Wang, Xi Luo et al.· Scientific Reports· 0 citations
The homeobox transcription factor MEIS2 is a crucial regulator of developmental processes, including embryogenesis and neurogenesis. However, its role in cancer progression and prognosis remains poorly understood across various human malignancies. This study evaluated the expression profile of MEIS2 in different canc...
Abdulrahman E. Algarni· Cancer Research· 0 citations
Silencing of TMEM33 markedly suppresses CRC cell proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) both in vitro and in vivo, and significantly reduces subcutaneous tumor growth and pulmonary metastatic burden.
Rui Li, Li Zhao, Nan-Nan Chai et al.· Human Cell· 0 citations
ABSTRACT 5‐Methylcytosine (m5C) is a vital RNA modification that regulates mRNA stability, splicing, and nuclear export. As a key m5C reader, ALYREF promotes tumorigenesis across various cancers; however, its precise role in endometrial cancer (EC) remains unknown. ALYREF expression and clinical significance in EC were...
Lin-Lin Hao, Jian Zhang, Qi Qian et al.· Advancement of science· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.